comparemela.com

Latest Breaking News On - சூரியன் மருந்து தொழில் - Page 1 : comparemela.com

Sun Pharma gains after licensing agreement with Ferring Pharma for Caritec in India

Sun Pharmaceutical Industries rose 1.01% to Rs 678 after the company said that it has entered into a license agreement with Ferring Pharmaceuticals to commercialize obstetric drug, Caritec in India.Sun Pharmaceutical Industries announced that one of its wholly owned subsidiaries has entered into a license agreement with Ferring Pharmaceuticals (Ferring), a subsidiary of Switzerland-based biopharmaceuticals MNC Ferring Pharmaceuticals, to commercialize a Room Temperature Stable (RTS) formulation of obstetric drug, Caritec (Carbetocin RTS) in India. Caritec is indicated for the prevention of excessive bleeding in women after vaginal or caesarean child birth. The condition is commonly known as post-partum hemorrhage (PPH). As per agreement terms, Sun Pharma is granted rights for co-marketing of the drugin India in the private market under the brand name Caritec. Ferring has developed the drug and received approval from the Drugs Controller General of India (DCGI) for introducing the

TCS, Sun Pharma, Eicher Motors in focus

Read more about TCS, Sun Pharma, Eicher Motors in focus on Business Standard. Tata Consultancy Services (TCS) said that the company has completed acquisition of GE s stake in TCS Saudi Arabia on May 26.

Nifty hits record high; breadth strong

Read more about Nifty hits record high; breadth strong on Business Standard. Key benchmark indices are trading firm in early trade on buying demand in index pivotals. At 9:25 IST, the barometer index, the S&P BSE Sensex, was up 286.18 points or 0.56% at 51,401.40. The Nifty 50 index was up 99.85 points or 0.65% at

Sun Pharmas Q4 PAT jumps 124% to Rs 894 cr

Read more about Sun Pharmas Q4 PAT jumps 124% to Rs 894 cr on Business Standard. On a consolidated basis, Sun Pharmaceutical Industries net profit surged 123.62% to Rs 894.15 crore on 4.13% increase in total revenue from operations to Rs 8,522.98 crore in Q4 March 2021 over Q4 March 2020.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.